BioCentury | Aug 28, 2020
Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

Concarlo is developing targeted therapies for metastatic breast cancer that take aim at both CDK4/6-driven cell proliferation and CDK2-driven drug resistance in one go.  The company spun out of SUNY...
BioCentury | Oct 2, 2018
Company News

FDA approves Paratek antibiotics

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) received a pair of FDA approvals Tuesday for Nuzyra omadacycline and Seysara sarecycline. The agency approved Nuzyra to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections...
BioCentury | Sep 14, 2018
Finance

Zai shores up

As Zai Lab Ltd. (NASDAQ:ZLAB) prepares for its first product launch, more clinical work and additional deals to fortify its pipeline, the company passed on the chance to list on Hong Kong’s new biotech chapter,...
BioCentury | Aug 10, 2018
Clinical News

FDA panel votes in favor of Paratek's antibiotic

FDA's Antimicrobial Drugs Advisory Committee voted in favor of IV and oral formulations of omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The amniomethylcycline antibiotic's PDUFA date is in early October. The panel voted that there is...
BioCentury | Jun 22, 2018
Clinical News

FDA panel to review Paratek antibiotic

FDA's Antimicrobial Drugs Advisory Committee scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The agency is reviewing oral and IV versions of the amniomethylcycline antibiotic to treat...
BioCentury | Jun 20, 2018
Company News

FDA panel to review Paratek antibiotic

FDA's Antimicrobial Drugs Advisory Committee has scheduled an Aug. 8 meeting to discuss two NDAs for omadacycline from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The agency is reviewing oral and IV versions of the amniomethylcycline antibiotic to...
BioCentury | Jun 5, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains; other Circular single-stranded DNA (CSSD)-based PTK7-targeting aptamers could be used to deliver cancer therapies. The aptamers consist of CSSD engineered to target PTK7 -- a protein expressed on many cancers -- and...
BioCentury | Apr 6, 2018
Clinical News

Paratek gets October PDUFA for omadacycline

FDA accepted and granted Priority Review to two NDAs from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) for omadacycline to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA dates are...
BioCentury | Apr 5, 2018
Company News

Priority Review for Paratek's antibiotic

FDA accepted and granted Priority Review to two NDAs from Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) for omadacycline to treat community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSIs). The PDUFA dates are...
BioCentury | Jan 5, 2018
Clinical News

Paratek begins rolling NDA of omadacycline for ABSSSIs and CABP

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) began submission of a rolling NDA to FDA for omadacycline (ZL-2401) to treat acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP). The company expects to complete...
Items per page:
1 - 10 of 102